Zobrazeno 1 - 10
of 216
pro vyhledávání: '"Zhongsheng Tong"'
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 12 (2024)
PurposeTriple-negative breast cancer (TNBC) is a highly challenging subtype due to a unique tumor microenvironment. Several evidence (IMpassion130 trial and KEYNOTE-355 trial) supported the therapeutic effect of the immune checkpoint inhibitor in TNB
Externí odkaz:
https://doaj.org/article/901f6abc1a054eb88802dcefa94eb9fc
Autor:
Zhi-Ming Shao, Li Cai, Shusen Wang, Xichun Hu, Kunwei Shen, Haibo Wang, Huiping Li, Jifeng Feng, Qiang Liu, Jing Cheng, Xinhong Wu, Xiaojia Wang, Hongyuan Li, Ting Luo, Jinping Liu, Khalid Amin, Khemaies Slimane, Yongping Qiao, Yongmin Liu, Zhongsheng Tong
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Background The global BOLERO-2 trial established the efficacy and safety of combination everolimus (EVE) and exemestane (EXE) in the treatment of estrogen receptor positive (ER +), HER2-, advanced breast cancer (ABC). BOLERO-5 investigated t
Externí odkaz:
https://doaj.org/article/54f05c5481a746a1854d62942484ed79
Autor:
Qiao Li, Ying Cheng, Zhongsheng Tong, Yunjiang Liu, Xian Wang, Min Yan, Jianhua Chang, Shusen Wang, Caiwen Du, Liang Li, Chunjiao Wu, Mingxia Wang, Zhuo Wang, Zhuli Wu, Xingli Wang, Yongli Jin, Lei Diao, Yi Sun, Yongjiao Zhang, Ai-Min Hui, Binghe Xu
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract Currently approved HER2-targeting antibody-drug conjugates (ADCs) for HER2-positive breast cancer (BC) are associated with safety concerns. In this multicenter, single-arm, dose-escalation (phase 1a) and dose-expansion (phase 1b) phase 1 tri
Externí odkaz:
https://doaj.org/article/a970daa7143b4f0c9d62cb86b63129d8
Autor:
Jiani Wang, Zhongsheng Tong, Yinuo Tan, Yehui Shi, Yun Wu, Qing Zhou, Xiaoyan Xing, Xiaomei Chen, Fuming Qiu, Fei Ma
Publikováno v:
Cell Reports Medicine, Vol 5, Iss 9, Pp 101707- (2024)
Summary: This phase 1a study assesses ESG401 in patients with heavily pretreated locally advanced or metastatic solid tumors, focusing on metastatic breast cancer. Forty patients are enrolled: three experience dose-limiting toxicities, establishing t
Externí odkaz:
https://doaj.org/article/736f4c38ba8e4e2ca5a20e6083c652d7
Autor:
Lei Zhu, Xin Yang, Jiying Zhang, Shuling Wang, Yulong Wang, Xing Wan, Xiang Zhu, Xiuyu Song, Zhongsheng Tong, Meng Yang, Weipeng Zhao
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 12 (2024)
IntroductionBreast cancer is a heterogeneous disease comprising various molecular subtypes, including Luminal A, Luminal B, human epidermal growth factor receptor-2 (HER2) positive, and triple negative types, each with distinct biological characteris
Externí odkaz:
https://doaj.org/article/4cf5e40b219543aa90019ee2552ec1b4
Autor:
Zhimin Shao, Zhongsheng Tong, Qiang Liu, Wei Li, Li Cai, Kunwei Shen, Huiping Li, Chuan Wang, Jin Yang, Zhenchuan Song, Shui Wang, Ting Luo, Wenhe Zhao, Haibo Wang, Yueyin Pan, Jianyun Nie, Xiaohua Zeng, Yanqing Bai, Wendy Chiang, Valeria Guarnaccia, Yu Bi, Binghe Xu
Publikováno v:
Cancer Medicine, Vol 13, Iss 15, Pp n/a-n/a (2024)
Abstract Background The MONALEESA‐7 and ‐2 phase 3 randomized trials demonstrated a statistically significant progression‐free survival (PFS) and overall survival (OS) benefit with initial ribociclib + endocrine therapy (ET) versus placebo + ET
Externí odkaz:
https://doaj.org/article/5f10b8954d0f46d9bd0df396e2893032
Publikováno v:
Discover Oncology, Vol 14, Iss 1, Pp 1-22 (2023)
Abstract Background Triple-negative breast cancer (TNBC) is a subtype of breast cancer with limited treatment options and poor prognosis. This study aimed to identify potential therapeutic targets based on the expression profiles of differentially ex
Externí odkaz:
https://doaj.org/article/ef26b89ecf9747c6a675992f218f99cf
Autor:
Binghe Xu, Qingyuan Zhang, Xichun Hu, Qing Li, Tao Sun, Wei Li, Quchang Ouyang, Jingfen Wang, Zhongsheng Tong, Min Yan, Huiping Li, Xiaohua Zeng, Changping Shan, Xian Wang, Xi Yan, Jian Zhang, Yue Zhang, Jiani Wang, Liang Zhang, Ying Lin, Jifeng Feng, Qianjun Chen, Jian Huang, Lu Zhang, Lisong Yang, Ying Tian, Hongyan Shang
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 13, Iss 5, Pp 2250-2258 (2023)
Entinostat plus exemestane in hormone receptor-positive (HR+) advanced breast cancer (ABC) previously showed encouraging outcomes. This multicenter phase 3 trial evaluated the efficacy and safety of entinostat plus exemestane in Chinese patients with
Externí odkaz:
https://doaj.org/article/29416e726eef485fb5be6cf4325c42c0
Publikováno v:
Thoracic Cancer, Vol 14, Iss 1, Pp 68-72 (2023)
Abstract Objective Our study evaluated the renal safety of abemaciclib plus endocrine therapy (ET) with bisphosphonate as a treatment option for hormone receptor positive, human epidermal growth factor receptor 2 (HER‐2) negative (HR+/HER2−) adva
Externí odkaz:
https://doaj.org/article/ff1e1d1cef0c4789a4874d61e4989e18
Autor:
Qingyuan Zhang, Bin Shao, Zhongsheng Tong, Quchang Ouyang, Yuting Wang, Guoying Xu, Shaorong Li, Huiping Li
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-10 (2022)
Abstract Background Strategies to improve activity of immune checkpoint inhibitors for triple-negative breast cancer (TNBC) are needed. Preclinical studies showed that antiangiogenic agents and poly (ADP-ribose) polymerase (PARP) inhibitors might sen
Externí odkaz:
https://doaj.org/article/6d9c4e5bbc544de18891ded04887530a